<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227822</url>
  </required_header>
  <id_info>
    <org_study_id>STRONG SFA study</org_study_id>
    <secondary_id>NL43610.060.13</secondary_id>
    <nct_id>NCT03227822</nct_id>
  </id_info>
  <brief_title>Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease</brief_title>
  <acronym>STRONG</acronym>
  <official_title>Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease; a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the length of lesion seems to be negatively associated with stent patency due to
      restenosis, it is thought that the efficacy of treatment in patients with multiple (&gt; 1)
      short (focal; &gt; 1 and &lt; 5 cm) SFA lesions can be improved by spot stenting as compared to the
      use of one long stent. This study proposes to evaluate the endovascular treatment for
      patients with SFA lesions by comparing two strategies for patients with extensive occlusive
      SFA disease; 1) short spot (SS) stenting or 2) long lesion (LL) stenting.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to include the number of patients
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">February 1, 2015</completion_date>
  <primary_completion_date type="Actual">February 1, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>absence of binary restenosis (≥ 50% re-obstruction) of the target lesion without interval clinically driven reintervention</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Extensive Occlusive Disease of Superficial Femoral Artery</condition>
  <arm_group>
    <arm_group_label>Short spot stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short spot stenting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long lesion stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long lesion stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Short spot stenting</intervention_name>
    <arm_group_label>Short spot stenting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Long lesion stenting</intervention_name>
    <arm_group_label>Long lesion stenting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PAOD (ABI &lt;0.90 and/or a decline of &gt;0.15 after exercise test), Rutherford category 2,
             3 or 4

          -  Multiple (&gt;1) short (focal; &gt;1 and &lt; 5 cm) significant stenoses (≥ 50%) and/or
             occlusions in the superficial femoral artery

          -  Eligible for endovascular treatment via short spot stenting and via long lesion
             stenting according to international guidelines

          -  Unilateral occlusive disease

          -  Age ≥ 18

        Exclusion Criteria:

          -  Patients with PAOD Rutherford category 5 and 6

          -  Impaired inflow due to significant lesions in the arteries proximal to the SFA
             intended to treat

          -  Bilateral lesions with treatment indication

          -  Contra-indication for anticoagulant therapy

          -  Renal insufficiency (MDRD &lt; 50 ml/min)

          -  Life expectancy &lt; 6 months

          -  Known contrast allergy

          -  Pregnancy

          -  Unable to complete a questionnaire in the home language
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>Marc van Sambeek</investigator_full_name>
    <investigator_title>MD, PhD, vascular surgeon</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

